Will Carl Icahn Take Herbalife Private?

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Will Carl Icahn Take Herbalife Private?

© courtesy of Herbalife Ltd.

Herbalife Ltd. (NYSE: HLF) has been the subject of much conflict in recent years as activist investor Bill Ackman is waging all-out war on the company, claiming that it is a pyramid scheme. However, it would seem that Herbalife has now received more reinforcements in the form of another activist investor willing to take a larger stake in the company.

This week at the Delivering Alpha conference, Carl Icahn in an interview discussed how he has asked the Federal Trade Commission (FTC) if he is able to take up to a 50% stake in Herbalife, essentially creating a bulkhead against the waves of Ackman’s short position.

Icahn only has permission to acquire up to a still sizable 35%. Currently he is only sitting at 20% of the float.

At Delivering Alpha, Icahn even went as far to mention that he has weighed the possibility of launching a tender offer for Herbalife, which could do some serious damage to Ackman’s position and seemingly set a price level for the stock.

[nativounit]

Along this line, Icahn believes that Herbalife might be better off as a privately held firm, but there’s still more to be seen from this company.

Excluding Wednesday’s move, Herbalife has outperformed the broad markets, with the stock up nearly 12% year to date. Over the past 52 weeks, the stock is up only 6%.

In terms of a broader perspective on the markets, Icahn commented on the current economic situation at CNBC’s Delivering Alpha, saying:

You look at the environment, and I think it’s very dangerous. You’re working on a ledge and you might make it to the end, but you fall off that ledge and you’re really going to see trouble.

Who knows, he could be talking to Ackman.

Shares of Herbalife were last seen up 4.8% at $62.68 on Wednesday, with a consensus analyst price target of $18.80 and a 52-week trading range of $42.26 to $72.22.

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618